The Tryptophan-kynurenine Pathway in Immunomodulation and Cancer Metastasis

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Aug 30

PMID 37644823

Authors

Charlise Basson

June Cheptoo Serem

Yvette Nkondo Hlophe

Priyesh Bipath

Affiliations

Soon will be listed here.

Abstract

Introduction: The activation of the kynurenine pathway in cancer progression and metastasis through immunomodulatory pathways has drawn attention to the potential for kynurenine pathway inhibition. The activation of the kynurenine pathway, which results in the production of kynurenine metabolites through the degradation of tryptophan, promotes the development of intrinsically malignant properties in cancer cells while facilitating tumour immune escape. In addition, kynurenine metabolites act as biologically active substances to promote cancer development and metastasis.

Methods: A literature review was conducted to investigate the role of the tryptophan-kynurenine pathway in immunomodulation and cancer metastasis.

Results: Evidence suggests that several enzymes and metabolites implicated in the kynurenine pathway are overexpressed in various cancers. As such, the tryptophan pathway represents a promising target for cancer treatment. However, downstream signalling pathways, including aryl hydrocarbon receptor activation, have previously induced diverse biological effects in various malignancies, which resulted in either the promotion or the inhibition of metastasis.

Conclusion: As a result, a thorough investigation of the kynurenine pathway and its regulatory mechanisms is necessary in order to properly comprehend the effects of kynurenine pathway activation involved in cancer development and metastasis.

Citing Articles

Modulation of the Neuro-Cancer Connection by Metabolites of Gut Microbiota.

Mafe A, Busselberg D Biomolecules. 2025; 15(2).

PMID: 40001573 PMC: 11853082. DOI: 10.3390/biom15020270.

Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy.

Khan T, Nagarajan M, Kang I, Wu C, Wangpaichitr M J Pers Med. 2025; 15(2).

PMID: 39997327 PMC: 11856717. DOI: 10.3390/jpm15020050.

Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer.

Rogovskii V, Murugin V, Vorobyev N, Popov S, Sturov N, Krasheninnikov A Front Pharmacol. 2025; 15():1503317.

PMID: 39850551 PMC: 11754188. DOI: 10.3389/fphar.2024.1503317.

Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.

Long-term exposure to BAY2416964 reduces proliferation, migration and recapitulates transcriptional changes induced by AHR loss in PyMT-induced mammary tumor cells.

Olafsen N, Das S, Gorrini C, Matthews J Front Oncol. 2024; 14:1466658.

PMID: 39450255 PMC: 11499230. DOI: 10.3389/fonc.2024.1466658.

References

Badawy A, Guillemin G . The Plasma [Kynurenine]/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal. Int J Tryptophan Res. 2019; 12:1178646919868978. PMC: 6710706. DOI: 10.1177/1178646919868978. View

Venkateswaran N, Conacci-Sorrell M . Kynurenine: an oncometabolite in colon cancer. Cell Stress. 2020; 4(1):24-26. PMC: 6946015. DOI: 10.15698/cst2020.01.210. View

Safe S, Lee S, Jin U . Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci. 2013; 135(1):1-16. PMC: 3748760. DOI: 10.1093/toxsci/kft128. View

Walczak K, Langner E, Makuch-Kocka A, Szelest M, Szalast K, Marciniak S . Effect of Tryptophan-Derived AhR Ligands, Kynurenine, Kynurenic Acid and FICZ, on Proliferation, Cell Cycle Regulation and Cell Death of Melanoma Cells-In Vitro Studies. Int J Mol Sci. 2020; 21(21). PMC: 7663343. DOI: 10.3390/ijms21217946. View

Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara G . Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002; 196(4):459-68. PMC: 2196046. DOI: 10.1084/jem.20020121. View

Quintero-Fabian S, Arreola R, Becerril-Villanueva E, Torres-Romero J, Arana-Argaez V, Lara-Riegos J . Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol. 2020; 9:1370. PMC: 6915110. DOI: 10.3389/fonc.2019.01370. View

Ye Z, Yue L, Shi J, Shao M, Wu T . Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications. J Cancer. 2019; 10(12):2771-2782. PMC: 6584917. DOI: 10.7150/jca.31727. View

Cheong J, Sun L . Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities. Trends Pharmacol Sci. 2017; 39(3):307-325. DOI: 10.1016/j.tips.2017.11.007. View

Walczak K, Wnorowski A, Turski W, Plech T . Kynurenic acid and cancer: facts and controversies. Cell Mol Life Sci. 2019; 77(8):1531-1550. PMC: 7162828. DOI: 10.1007/s00018-019-03332-w. View

10.

Mailankot M, Staniszewska M, Butler H, Caprara M, Howell S, Wang B . Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens. Lab Invest. 2009; 89(5):498-512. PMC: 2722445. DOI: 10.1038/labinvest.2009.22. View

11.

Mondanelli G, Mandarano M, Belladonna M, Suvieri C, Pelliccia C, Bellezza G . Current Challenges for IDO2 as Target in Cancer Immunotherapy. Front Immunol. 2021; 12:679953. PMC: 8097162. DOI: 10.3389/fimmu.2021.679953. View

12.

Chen Y, Zhang J, Yang Y, Xiang K, Li H, Sun D . Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression. J Cell Physiol. 2022; 237(12):4339-4355. DOI: 10.1002/jcp.30876. View

13.

Xie N, Zhang L, Gao W, Huang C, Huber P, Zhou X . NAD metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020; 5(1):227. PMC: 7539288. DOI: 10.1038/s41392-020-00311-7. View

14.

Lim J, Lee S, Park G, Choi E, Min C . Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model. Exp Hematol. 2014; 42(10):862-6.e3. DOI: 10.1016/j.exphem.2014.06.006. View

15.

Badawy A . Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci Rep. 2022; 42(11). PMC: 9653095. DOI: 10.1042/BSR20221682. View

16.

Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D . Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2009; 67(3):361-5. DOI: 10.1016/j.lungcan.2009.05.001. View

17.

Ait-Belkacem R, Bol V, Hamm G, Schramme F, Van den Eynde B, Poncelet L . Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology. SLAS Discov. 2017; 22(10):1182-1192. DOI: 10.1177/2472555217712659. View

18.

Zhai L, Bell A, Ladomersky E, Lauing K, Bollu L, Sosman J . Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185. PMC: 7308527. DOI: 10.3389/fimmu.2020.01185. View

19.

Xue P, Fu J, Zhou Y . The Aryl Hydrocarbon Receptor and Tumor Immunity. Front Immunol. 2018; 9:286. PMC: 5816799. DOI: 10.3389/fimmu.2018.00286. View

20.

Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S . Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2006; 25(6):981-93. PMC: 11529496. DOI: 10.1007/s10571-005-8469-y. View